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Abstract 
 
THIP (Gaboxadol) is a selective GABAA agonist, acting in vitro with high potency and 
efficacy at the extrasynaptic GABAA containing receptors. THIP was suggested to be a 
potential hypnotic to treat insomnia and it is currently in clinical trial. Here we assessed 
whether the GABAA -containing receptors mediate in vivo the effect of THIP on sleep and 
the sleep electroencephalogram (EEG). We performed EEG recordings in a mouse model 
deficient in the GABAA -subunit gene (
-/-
 mice) and in wild-type littermate controls. THIP 
(4 and 6 mg/kg intraperitoneally) induced an abnormal EEG pattern resulting in dramatic 
changes in the waking and nonREM sleep EEG spectra in wild-type mice. Indeed, a massive 
increase in EEG power lasting 2-3 hours occurred in both the frontal and parietal derivation, 
especially in frequencies below 6 Hz. All effects were more prominent in the frontal EEG. 
Furthermore, the highest dose of THIP lengthened REM sleep latency and suppressed REM 
sleep. In contrast, vigilance states and sleep latencies were not affected in -/- mice. Moreover 
only minor changes were observed in the nonREM sleep EEG spectrum after THIP injection 
in the -subunit deficient mice. The present findings do not indicate a sleep-promoting effect 
of THIP in mice, which is in accordance with a previous report in this species. Moreover, our 
results in vivo demonstrate that THIP acts preferentially at GABAA receptors containing the 
delta subunit.  
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Introduction 
 
Targeting the central GABA neurotransmitter system has been shown to have 
therapeutic relevance for specific clinical conditions, including sleep disorders. GABAA 
receptors are hetero-pentameric complexes assembled from seven subunit classes 
(). The subunit composition and the regional distribution of the 
GABAA receptors are major factors underlying the differentiation of the effects of therapeutic 
agents (Rudolph & Mohler, 2006). A specific GABAA receptor agonist, THIP (4,5,6,7-
Tetrahydroisoxazolo-[5,4-c]pyridine-3-ol), also named Gaboxadol, is currently under 
investigation for its potential to treat insomnia (Krogsgaard-Larsen et al., 1977; Ebert et al., 
2006). In vitro studies using recombinant GABAA receptors demonstrated that THIP interacts 
with high potency and efficacy at 43-, 43- and 63-containing receptors (Adkins et 
al., 2001; Brown et al., 2002; Storustovu & Ebert, 2006). Interestingly, the 43 receptor 
subtype is mainly expressed in regions involved in sleep regulation, such as the ventro-basal 
nucleus of the thalamus and the neocortex (Pirker et al., 2000; Peng et al., 2002). GABAA -
containing receptors show a predominant extrasynaptic localization (Nusser et al., 1998; Sun 
et al., 2004) and mediate non-desensitizing “tonic” inhibition, in contrast to “phasic” 
inhibition controlled by synaptic GABAA receptors (Farrant & Nusser, 2005; Jia et al., 2005). 
The presence of an extrasynaptic tonic current, sensitive to THIP, was recently demonstrated 
in the ventro-basal nucleus of the thalamus as well as in cortical layers II-III (Belelli et al., 
2005; Jia et al., 2005; Drasbek & Jensen, 2006). In addition, GABAA 4
-/-
 mice show a lack of 
tonic inhibition in the thalamic relay neurons (Chandra et al., 2006). The distinct 
  4 
electrophysiological properties of extrasynaptic 43 receptors may therefore underlie the 
specific effects of THIP. 
Effects of GABAA receptor agonists on sleep differ substantially from those evoked 
by GABAA receptor allosteric modulators such as benzodiazepines or benzodiazepine-like 
compounds. Rats treated with THIP (4 mg/kg) increased the amount of NREM sleep as well 
as slow-wave activity (SWA, EEG power in the 0.75-4 Hz frequency range; a measure of 
sleep intensity) within NREM sleep, independently of circadian time (Lancel & Faulhaber, 
1996; Lancel, 1997). In addition, THIP had no effect on REM sleep duration. These results 
suggested that THIP could be a potential therapeutic compound to treat insomnia. In healthy 
human subjects, a single oral bed-time dose of THIP promoted slow-wave sleep and enhanced 
EEG low-frequency activity in NREM sleep (Faulhaber et al., 1997; Lancel et al., 2001; 
Mathias et al., 2005). However, a recent study showed in mice that THIP elicited an increase 
in SWA not only in NREM sleep but also in the waking EEG (Vyazovskiy et al., 2005). The 
increase was due to the recurrent appearance of spike-wave events, their asymmetric shape, as 
well as an increase in EEG amplitude. This study also demonstrated that the changes induced 
by THIP were substantially different from those evoked by prolonging wakefulness for 
several hours.  
To further assess THIP’s functional selectivity at 43 receptors and its mechanism 
of action in vivo, we investigated sleep and the sleep EEG in a mouse model deficient in the 
-subunit gene. 
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Materials and Methods 
 
Animals 
GABAA delta subunit knockout 
-/-
 mice (n=6 males, n=4 females) and their wild-type 
littermates +/+ (n=6 males, n=5 females) were obtained from heterozygous breeding pairs and 
genotyped by PCR analysis of tail biopsies. A set of oligonucleotides (5′ primer: CTG TGA 
ATG TGG CGC TTG CCC TAG AG; 3′ primer: GTC CAG CAT GCA CTC CTG CTC ATC 
CAG) amplified a product (1866 bp and 766 bp for the -/- and +/+, respectively) 
corresponding to the allele of exon 4, using Eppendorf Mastercycler. PCR conditions were: 
96°C for 1 min; then 96°C for 15 sec, 51°C for 15 sec, 68°C for 1.5 min, 40 cycles. The mice 
were maintained on a mixed C57BL/6J x 129Sv/SvJ background (see (Mihalek et al., 1999), 
for characterization). Mice were housed individually with ad libitum access to food and water. 
The animal facility was maintained on a 12:12 hr light/dark cycle (light on at 9am;  60 lux), 
at a constant ambient temperature (22-24°C) with a 50 % relative humidity. All experimental 
procedures were carried out in accordance with the European Community Council Directive 
of 24 November 1986 (86/609/EEC) and were approved by the Cantonal Veterinary Office of 
Zurich. 
 
Surgery 
At surgery, mice were 11-13 weeks-old (-/-: males 23.8 ± 0.7 g, females 20.3 ± 0.4 g; +/+: 
males 23.5 ± 0.6 g, females 20.1 ± 0.5 g; no significant differences between -/-and +/+ mice). 
For electroencephalogram (EEG) recording, the mice were implanted epidurally under deep 
anesthesia (ketamine 100 mg/kg-xylasine 20 mg/kg, dose 10 ml/kg intraperitoneally (i.p.)). 
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Gold-plated miniature screws (diameter 0.9 mm) were positioned on the right hemisphere 
above the frontal cortex (1.5 mm anterior to bregma and 2 mm lateral to the midline) and the 
parietal cortex (2 mm posterior to bregma and 3 mm lateral to the midline). A reference 
electrode was placed above the cerebellum (2 mm posterior to lambda, on the midline). 
Electrodes were connected to stainless steel wires and fixed to the skull with dental cement. 
Two gold wires (diameter 0.2 mm) inserted bilaterally in the neck muscle were used to record 
the electromyogram (EMG). After at least 3 weeks recovery, the mice were placed in 
experimental cages for at least 3 days to adapt to the recording conditions.  
 
Experimental protocol 
The mice were injected i.p. with either 4 mg/kg THIP (4,5,6,7-Tetrahydroisoxazolo[5,4-
c]pyridine-3-ol hydrochloride; Tocris Bioscience, Bristol, UK) or saline (0.9 % NaCl) 3 hr 
after light onset, following a crossover design with at least one week between treatments. A 
third injection (THIP 6 mg/kg) was administered at least 7 days after the crossover treatment. 
The dose was chosen based on previous studies showing that THIP (2 mg/kg) did not induce 
significant changes in the EEG in C57BL/6 mice, and only minor changes on the EEG power 
spectrum in rats (Lancel & Faulhaber, 1996; Lancel, 1997; Vyazovskiy et al., 2005). At 3 h 
after light onset, EEG SWA in NREM sleep has dissipated considerably (Franken et al., 1999; 
Huber et al., 2000; Franken et al., 2001). Therefore, we chose this time point for injection as 
previously (Vyazovskiy et al., 2005) to test potential hypnotic effects of THIP by ensuring a 
possible increase of SWA in NREM sleep following THIP injection. Mice were observed by 
the investigator for 50-120 min after each injection and behavior was systematically 
monitored. In addition, motor activity was continuously recorded by an infra-red (IR) sensor 
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placed above the cage. Continuous EEG-EMG recordings were obtained throughout the 12 hr 
light periods.  
 
Data acquisition 
The EEG and EMG signals were amplified (amplification factor approx. 2000), conditioned 
by analogue filters (high-pass filter: -3dB at 0.016 Hz; low-pass filter: -3 dB at 40 Hz, less 
than -35 dB at 128 Hz.) sampled with 256 Hz, digitally filtered (EEG: low-pass FIR filter 25 
Hz; EMG: band-pass FIR 20-50 Hz) and stored with a resolution of 128 Hz. EEG power 
spectra were computed for consecutive 4 sec epochs by a Fast Fourier Transform routine 
within the frequency range of 0.25-25 Hz. Between 0.25 and 5 Hz, the 0.25 Hz bins were 
added to yield 0.5 Hz bins, and between 5.25 and 25 Hz to yield 1 Hz bins. 
 
Data analysis 
Based on the raw parietal and frontal EEG, the corresponding slow-wave activity values 
(SWA, EEG power between 0.75-4 Hz) as well as the raw and integrated EMG, the three 
vigilance states NREM sleep (low EMG and high EEG amplitude, high slow-wave activity), 
REM sleep (low EMG and low EEG amplitude, high theta activity – EEG power between 
6.25-9 Hz) and waking (high EMG and low EEG amplitude and high theta activity 
concomitant with highest EMG values) were visually scored for 4 sec epochs (Tobler et al., 
1997). In the first 90 min after THIP injection, the waking and NREM sleep EEG were often 
indistinguishable. Determination of vigilance states was then based on the EMG, IR activity, 
and the behavioral observations. Epochs containing EEG artifacts were identified and 
excluded from spectral analysis. 
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NREM sleep latency after treatment was defined, as previously (Kopp et al., 2004; 
Vyazovskiy et al., 2005), as time elapsed between the injection and the first NREM sleep 
episode lasting at least 1 min (and not interrupted by more than 6 consecutive 4 sec epochs, or 
by a cumulated total of 32 sec not scored as NREM sleep). In order to assess the effect of 
THIP on REM sleep latency, we determined the time elapsed between the beginning of the 
first NREM sleep episode and the occurrence of a REM sleep epoch. The 9 hr following THIP 
or vehicle injection were subdivided into 1.5 hr intervals. EEG power spectra were computed 
between 0.25-25 Hz for each vigilance state and expressed as percentage of the individual 
mean power density in the corresponding interval of saline injection, starting at light onset for 
the 12 hr light period. The software package MATLAB (The MathWorks, Inc., Natick, MA, 
USA) was used for data and signal analysis. 
Activity counts derived from the infra-red sensor were stored in 1 min epochs and 12 h mean 
activity profiles were computed (Stanford Software System, Chronobiology Kit). The effect 
of THIP on motor activity was investigated for the first three hours after injection of THIP 
and compared with saline control. 
 
Statistics 
For a given treatment, each mouse was referred to its own control represented by the data 
obtained after injection of saline. The effects of THIP and saline on EEG spectra were 
compared by two-way ANOVA factors ‘treatment’ (THIP and saline) x ‘1.5 hr interval’, 
followed by post-hoc paired t-test when significance was reached. Regional differences of 
EEG power in waking and NREM sleep between the frontal and parietal derivation after 
THIP (4 or 6 mg/kg i.p.) were analyzed for the three first 1.5 hr intervals after treatment 
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injection by two-way ANOVA factors ‘derivation’ (frontal and parietal) x ‘1.5 hr interval’, 
followed by post-hoc paired t-test when significance was reached.  
Vigilance states and sleep latency values are expressed as mean ± SEM (data were normally 
distributed as tested with the procedure Univariate; SAS). The effects of THIP were compared 
with the corresponding saline control, within each genotype, by one-way ANOVA factor 
‘treatment’ for each 1.5 hr interval. In case of significance, the ANOVA was followed by the 
Dunnett test for mean comparison. Subsequently, a two-way ANOVA factors ‘treatment’ x 
‘interval: mean int 1-2; 3’ was performed to compare the effect of THIP (i.e., first 1.5 hr 
interval after injection versus (vs) mean of the two 1.5 hr intervals prior to pharmacological 
treatment). To compare genotypes, statistical analyses were performed using two-way 
ANOVA for factors ‘treatment’ and ‘genotype’ followed by a post-hoc Dunnett test when 
significance was reached.  
Motor activity was analyzed within genotype by one-way ANOVA factor ‘treatment’. 
Genotypes were compared by two-way ANOVA factor ‘treatment’ x ‘genotype’.  
SAS package was used for statistical analysis (SAS Institute Inc., Cary, NC, USA). 
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Results 
We performed EEG recordings in GABAA receptor -subunit knockout mice and their 
+/+
 
littermates to investigate the effects of two doses of THIP (4 and 6 mg/kg i.p.) in comparison 
with saline control. No difference between the +/+ and -/- mice was found in the vigilance 
states scored for the 3 hr before treatments (not shown), as well as after saline injection (Table 
1). 
 
Sleep latency 
For both genotypes, NREM sleep latency and REM sleep latency showed a large variability 
after injection of THIP and saline (Table 1). REM sleep latency, after occurrence of the first 
NREM episode, was significantly lengthened by 6 mg/kg THIP in +/+ mice (one-way 
ANOVA factor ‘treatment’: p=0.0256). NREM sleep and REM sleep latencies did not differ 
in -/- mice after THIP injection compared to saline. Sleep latency after saline did not differ 
between the genotypes (Table 1). 
 
EEG spectra 
In +/+ mice, a massive increase in EEG power lasting 2-3 hours was observed in the waking 
period following THIP injection, as well as in the subsequent NREM sleep, in the frequencies 
below 5 Hz, corresponding to slow wave activity (Fig. 1 and 2). These effects were seen in 
both the parietal and frontal EEG derivation, being more prominent in the frontal EEG (two-
way ANOVA interaction ‘derivation’ x ‘1.5 hr interval’ was significant in waking at 1 Hz and 
2.5-18 Hz after 4 mg/kg THIP and at 1 Hz and 2.5-21 Hz after 6 mg/kg THIP; p<0.05 post-
hoc paired t-test; significant in NREM sleep at 2.5-3 Hz after 4 mg/kg THIP, at 1 Hz and 2-4 
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Hz after 6 mg/kg THIP; p<0.05 post-hoc paired t-test). In addition, the changes in the EEG 
spectrum showed a dose response both in waking and NREM sleep (Fig. 1 and 2).  
EEG spectra in waking. Specifically, in the waking EEG obtained from the frontal derivation, 
THIP induced a significant increase in EEG power in a broad frequency range comprising 
between 0.75-21 Hz (two-way ANOVA interaction ‘treatment’ x ‘1.5 hr interval’ was 
significant after 4 and 6 mg/kg THIP; p<0.05 post-hoc paired t-test). This effect dissipated 
within 3-4 hr after injection (Fig. 1). In the parietal derivation, THIP induced a significant 
increase in frequencies between 0.75-6 Hz (two-way ANOVA interaction ‘treatment’ x ‘1.5 
hr interval’ was significant after 4 and 6 mg/kg THIP; p<0.05 post-hoc paired t-test; not 
shown). The surge of SWA (0.75-4 Hz band) occurred during the first 90 minutes in both 
EEG derivations. The magnitude of the increase was dose-dependent (during the first 1.5 hr 
interval, in the frontal derivation, the maximal increase in the slow wave band was in waking 
600-fold and 670-fold above the corresponding saline after 4 and 6 mg/kg, respectively). In 
contrast, THIP induced only a slight, non significant, increase in the waking spectra of the -/- 
mice (p values ranging from 0.1162-0.9958 for the SWA frequency range after two-way 
ANOVA interaction ‘treatment’ x ‘1.5 hr interval’) (Fig. 1). 
EEG spectra in NREM sleep. In NREM sleep, EEG power was increased in the lower 
frequencies after both the 4 and 6 mg/kg THIP dose (two-way ANOVA interaction 
‘treatment’ x ‘1.5 hr interval’ was significant between 0.75-5 Hz and 0.75-4 Hz in the frontal 
and parietal derivation respectively; p<0.05 post-hoc paired t-test) (Fig. 2). This effect lasted 
3-4 hr after injection and dissipated thereafter. THIP also induced an EEG power decrease at 
frequencies between 10-19 Hz during the first 1.5 hr after injection in the frontal EEG (two-
way ANOVA interaction ‘treatment’ x ‘1.5 hr interval’ was significant after 4 and 6 mg/kg 
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THIP; p<0.05 post-hoc paired t-test; Fig. 2). In -/- mice, a minor increase in NREM sleep 
EEG power was observed after injecting THIP 4 or 6 mg/kg for frequencies below 4 Hz (two-
way ANOVA interaction ‘treatment’ x ‘1.5 hr interval’ was significant for the 3.5 Hz 
frequency in the frontal derivation; p<0.05 post-hoc paired t-test; p values after ANOVA 
showed a trend for 2.5-3 Hz; p=0.0607 and 0.0698) (Fig. 2).  
Regarding the effect of THIP observed in +/+ mice in the low EEG frequencies (i.e., SWA), 
caution is warranted. Indeed, THIP consistently elicited an abnormal EEG pattern 
characterized by recurring spike-wave events both in waking and NREM sleep (Fig. 3). These 
spike-wave events, recurring at a frequency of approximately 0.5-1 Hz, largely contributed to 
the SWA increase in the spectrum. This abnormal EEG pattern was previously reported in rat 
(Lancel & Faulhaber, 1996; Lancel, 1997) and analyzed in detail in the mouse (Vyazovskiy et 
al., 2005). 
 
Vigilance states 
After 4 and 6 mg/kg THIP injection in +/+ mice, waking and NREM sleep were not affected 
significantly. However, waking tended to increase with a concomitant reduction in NREM 
sleep (Table1: one-way ANOVA factor ‘treatment’: p=0.0531 and p=0.0823 for waking and 
NREM sleep, respectively). REM sleep was significantly suppressed by 6 mg/kg THIP (one-
way ANOVA factor ‘treatment’: p=0.0070; post-hoc Dunnett test p<0.05 for THIP 6 mg/kg 
vs saline). The effects of THIP on vigilance states dissipated after the first 1.5 hr interval. We 
further compared the effects of THIP during the first 1.5 hr after injection with the three first 
hr of the light period preceding injection. THIP enhanced the time spent in waking with a 
concomitant decrease in NREM sleep and REM sleep (2-way ANOVA factors ‘treatment’ x 
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‘interval: mean int 1-2; 3’: p=0.0111; p=0.0182 and p=0.0059 for waking, NREM sleep and 
REM sleep, respectively). In contrast, the vigilance states were not affected significantly by 
THIP in -/- mice (Table 1: two-way ANOVA factors ‘treatment’ x ‘interval: mean int 1-2; 3’ 
not significant).  
 
Motor activity 
The analysis of infra-red activity for the first three hours after injection showed no difference 
in mean counts per hour between saline and THIP treatment (mean counts per hr  SEM: WT 
saline, THIP 4 mg/kg, 6 mg/kg: 379.9  27.2, 366.4  47.9, 294.4  28.6; KO saline, THIP 4 
mg/kg, 6 mg/kg: 392.5  27.1, 358.7.4  33.4, 337.2  30.2; one-way ANOVA factor 
‘treatment’ and two-way ANOVA factors ‘genotype’ x ‘treatment’ and interaction were not 
significant). 
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Discussion 
 
This is the first study demonstrating that the effects of THIP on the EEG and on sleep were 
virtually eliminated by genetic inactivation of the GABAA subunit containing receptor. The 
present results show that THIP elicited only minor changes in GABAA 
-/-
 mice, in contrast to 
their +/+ littermates which displayed dramatic alterations in their cortical EEG after THIP. 
Our results suggest that in vivo THIP acts preferentially via GABAA receptors containing the 
 subunit. This finding is in accordance with a recent study showing that THIP (30 mg/kg s.c.) 
induced a 50% loss of righting reflex in GABAA 
-/- 
mice (Boehm et al., 2006). GABAA 
-/- 
mice also displayed a greatly reduced sensitivity to THIP (10 and 15 mg/kg, i.p.) as assessed 
by behavioral paradigms including rotarod, tail flick assay and open field assay (Chandra et 
al., 2006). Interestingly, neuroanatomical data showed a decreased expression of the 4 
subunit in the GABAA 
-/-
 mice (Peng et al., 2002). Reciprocally, preliminary studies 
suggested a decreased expression of the  subunit in 
-/- 
mice (Chandra et al., 2006).  
The time course of THIP effects we observed in the +/+ mice is consistent with 
pharmacokinetic studies showing that THIP can cross the blood brain barrier, the highest 
concentration of drug being observed in the brain 30 min after administration. Its half-life was 
shown to be 1.4 hours in mice (Schultz et al., 1981). In addition, THIP is a poor substrate for 
reuptake into neurons and glia, and therefore likely to produce a more widespread tonic 
activation of GABAA receptors (Ebert et al., 2002). Therefore, THIP administration might 
elicit a sustained increase in tonic inhibition.  
Consistent with previous reports, we observed that THIP induced recurring spike-wave events 
(Lancel & Faulhaber, 1996; Lancel, 1997; Vyazovskiy et al., 2005). THIP modified 
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dramatically the patterns of electrical activity and thus the biochemical states of neurons. It 
was shown that relatively minor changes in chloride concentrations in post-synaptic neurons 
can lead to a switch from inhibitory to excitatory activity (Marty & Llano, 2005). In addition, 
tonic inhibition in the thalamic and cortical slices was shown to be highly sensitive to THIP 
(Porcello et al., 2003; Belelli et al., 2005; Jia et al., 2005; Drasbek & Jensen, 2006). 
Therefore, the effect of THIP may result in quite profound alterations in properties of 
networks involved in sleep regulation. Interestingly, the general anesthetic etomidate, which 
potentiates GABAA receptor activity, elicited similar high amplitude, recurrent spike-like 
events (Reynolds et al., 2003). However, the origin of such EEG waveforms is still unknown.  
Our results do not provide evidence for a sleep-inducing action of THIP (4 and 6 mg/kg, i.p.) 
in mice. THIP did not shorten sleep latency but rather tended to increase the time spent in 
waking after injection. NREM sleep and REM sleep latencies were prolonged after 6 mg/kg 
THIP. Thus, in +/+ mice the effects of THIP were more evident in the waking EEG spectrum. 
In contrast, sleep latencies and time spent in the different vigilance states were not modified 
by THIP administration in -/- mice. Thus, in -/- mice the minor effects of THIP were 
observed already in the NREM sleep spectrum, while in the +/+ mice the main effects were 
seen in waking and dissipated in the subsequent NREM sleep due to the induction of waking 
after THIP injection. 
Interestingly, we observed a regional effect of THIP on the sleep EEG. In the frontal EEG, 
THIP enhanced the power spectrum in a broad frequency range, both in waking (0.75-21 Hz) 
and NREM sleep (encompassing the SWA band, as well as frequencies between 10-19 Hz), 
while in the parietal derivation its effects were restricted mainly to the SWA range. A 
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topographical difference on the sleep EEG was previously reported in mice after 
administration of diazepam (Kopp et al., 2003). 
Other drugs have been shown to increase SWA, including Tiagabine, a GABA uptake 
inhibitor which results in elevating the synaptic GABA levels and therefore may enhance 
tonic inhibition. Tiagabine partially mimics the effect of THIP: it elicited recurrent episodes 
of hypersynchronous EEG signals in both waking and NREM sleep in rat. Tiagabine elevated 
EEG activity in frequencies between 1-8 Hz and 11-16 Hz in NREM sleep in rats (Lancel et 
al., 1998). In healthy elderly subjects, slow-wave sleep, SWA and sleep efficiency were 
increased after Tiagabine (Mathias et al., 2001; Walsh et al., 2005). Furthermore, recent 
studies evaluated the impact of these drugs on sustained attention and cognitive performance. 
In healthy human subjects, Tiagabine counteracted the effects of sleep restriction on sustained 
vigilance attention (Walsh et al., 2006), and elderly subjects did not show any impairment of 
next day attention and memory function after three consecutive treatment nights with THIP 
(Mathias et al., 2005). We observed massive effects of THIP on cortical EEG power density. 
The potential consequences of these changes on performance (i.e., improvement or 
impairment of learning, memory consolidation and retrieval) need to be further investigated. 
In summary, our findings suggest that GABAA 43 receptors mediate the effect of THIP on 
the cortical waking and NREM sleep EEG. GABAA 43 receptors have been shown to 
mediate tonic currents which are highly sensitive to THIP in thalamic relay neurons. Thus, the 
lack of response of the -/- mice indicates the importance of tonic inhibition in the regulation 
of fast oscillatory EEG activities occurring during the wake state, as well as the low frequency 
rhythms typical for NREM sleep. 
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Table 1. Effect of THIP on vigilance states and sleep latency 
Data are mean values (min ± SEM) after saline or THIP (4 and 6 mg/kg). * p<0.05, post-hoc 
Dunnett test when significance was reached for one-way ANOVA factor ‘treatment’. 
Comparison between genotypes was performed by two-way ANOVA factors ‘genotype’ x 
‘treatment’, followed by post-hoc Dunnett test († p<0.05). 
 
 
+/+ 
  -/- 
 Saline THIP 
4 mg/kg 
(n=9) 
THIP 
6 mg/kg 
(n=10) 
 Saline THIP 
4 mg/kg 
(n=9) 
THIP 
6 mg/kg 
(n=9) 
Waking 54.5 ± 5.3 68.5 ± 6.2 73.2 ± 5.1  53.8 ± 4.9 51.8 ± 2.6 49.0 ± 3.6 
NREM sleep 31.7 ± 4.5 19.6 ± 5.7 16.3 ± 5.0  32.0 ± 4.4 34.6 ± 2.3 37.0 ± 3.1 
REM sleep 3.8 ± 0.9 1.9 ± 0.7 0.5 ± 0.2*  4.2 ± 0.8 3.6 ± 0.6 3.9 ± 0.8 
Latency to NREM 
sleep 
43.2 ± 7.1 32.4 ± 7.6 67.6 ± 12.8  41.1 ± 6.8 37.3 ± 3.8 31.0 ± 3.2 
Latency to REM 
sleep (after onset of 
first NREM sleep 
episode) 
14.1 ± 2.1 23.9 ± 5.7 34.9 ± 7.0*  21.9 ± 4.6  24.0 ± 5.1 30.4 ± 5.1 
Latency to REM 
sleep (after injection) 
57.2 ± 6.9 86.3 ± 7.6*
, †
 102.5 ± 7.1*
, †
  63.0 ± 8.8  61.3 ± 3.3 61.4 ± 5.1 
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Figure legends  
 
Figure 1. EEG power density in the frontal derivation in waking for the first three 1.5 hr 
intervals after THIP (4 and 6 mg/kg) for knockout -/- mice and wild-type +/+ littermates. 
Mean values of relative EEG power density after THIP (4 mg/kg: n=9 for both genotypes; 6 
mg/kg: n=9 and n=10 for -/- and +/+, respectively) expressed as percentage of EEG power of 
the same bin in the corresponding interval after saline injection (=100 %). Note different y-
axis scaling for -/- and +/+mice. Values are plotted at the upper limit of each bin. Horizontal 
lines above the curves indicate frequency bins that differed significantly from the 
corresponding bins after saline (two-way ANOVA factor ‘treatment’ x ‘1.5 hr interval’; 
p<0.05 post-hoc paired t-test).  
 
Figure 2. EEG power density in NREM sleep (frontal derivation) for the first three 1.5 hr 
intervals after THIP (4 and 6 mg/kg) for knockout -/- mice and wild-type +/+ littermates. 
Mean values of relative EEG power density after THIP (4 mg/kg: n=9 for both genotypes; 6 
mg/kg: n=9 and n=10 for -/- and +/+, respectively) expressed as percentage of EEG power of 
the same bin in the corresponding interval after saline injection (=100 %). Note different y-
axis scaling for -/- and +/+mice. Horizontal lines above the curves indicate frequency bins 
that differed significantly from the corresponding bins after saline (two-way ANOVA factor 
‘treatment’ x ‘1.5 hr interval’; p<0.05 post-hoc paired t-test). 
 
Figure 3: Representative examples of 12 sec raw EEG (frontal derivation) and EMG traces in 
waking and NREM sleep, after saline or THIP (4 mg/kg) in +/+ control mice. 
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Fig. 2
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Fig. 3
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